| Product Name | VOCABRIA FILM-COATED TABLETS 30MG, VOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 ML, VOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML |
| Active Ingredient (Strength) | Cabotegravir Sodium eqv Cabotegravir(30mg), Cabotegravir(200mg/ml), Cabotegravir(200 mg/ml) |
| Product Registrant | GLAXOSMITHKLINE PTE LTD |
| Date of Approval | 20/01/2024 |
| Indications: Film-coated Tablets: VOCABRIA tablets are indicated in combination with rilpivirine tablets for short term (see Dosage and Administration) treatment of human immunodeficiency virus (HIV)-1 infection in adults who are virologically suppressed (HIV-1 RNA without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class): · oral lead-in to assess tolerability of cabotegravir prior to administration of long acting (LA) VOCABRIA injection. · oral therapy for adults who will miss planned dosing with VOCABRIA injection.Suspension for Injection: VOCABRIA injection is indicated in combination with rilpivirine injection for treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class (see Clinical studies). | |
| Product Name | CIBINQO FILM-COATED TABLET 50 MG, CIBINQO FILM-COATED TABLET 100 MG, CIBINQO FILM-COATED TABLET 200 MG |
| Active Ingredient (Strength) | Abrocitinib(50.00 mg), Abrocitinib(100.00 mg), Abrocitinib(200.00 mg) |
| Product Registrant | PFIZER PRIVATE LIMITED |
| Date of Approval | 12/01/2024 |
| Indications: CIBINQO is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents (age 12 years and above) who are candidates for systemic therapy and whose disease is not adequately controlled with topical medications or for whom topical treatments are otherwise medically inadvisable. | |
HSA: Health Sciences Authority
Link to the HSA announcement: https://www.hsa.gov.sg/announcements/new-drug-indication-approvals/new-drug-indication-approval—january-2024
Only Authentic Products and Genuine Medical Supplies, at POM Marketplace!
Login or Register now to access our comprehensive range of medical supplies.
Disclaimer: The information provided on this page is intended solely for healthcare professionals for informational purposes only. While we strive for accuracy, POMConnect assumes no liability for errors or omissions. The content here should not be considered a substitute for professional medical advice. POMConnect does not endorse specific treatments or external websites linked from this page. Please note that the information is accurate at the time of publication and does not account for any modifications or updates made to the original research article after its initial publish date. POM Marketplace is accessible to qualified healthcare professionals only. Any unauthorized access or use by individuals who do not meet this criteria is prohibited.
